BioMarin Pharmaceutical Inc. and Perrigo Company plc: SG&A Spending Patterns Compared

BioMarin vs. Perrigo: A Decade of SG&A Trends

__timestampBioMarin Pharmaceutical Inc.Perrigo Company plc
Wednesday, January 1, 2014302156000675200000
Thursday, January 1, 2015402271000771800000
Friday, January 1, 20164765930001205500000
Sunday, January 1, 20175543360001146500000
Monday, January 1, 20186043530001125800000
Tuesday, January 1, 20196809240001166100000
Wednesday, January 1, 20207376690001175500000
Friday, January 1, 20217593750001111400000
Saturday, January 1, 20228540090001210100000
Sunday, January 1, 20239373000001274600000
Monday, January 1, 20241009025000
Loading chart...

Unleashing the power of data

SG&A Spending Patterns: BioMarin vs. Perrigo

In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. BioMarin Pharmaceutical Inc. and Perrigo Company plc have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, BioMarin's SG&A expenses surged by approximately 210%, reflecting a strategic investment in growth and market expansion. In contrast, Perrigo's expenses increased by about 89%, indicating a more conservative approach.

A Decade of Financial Strategy

BioMarin's aggressive spending, peaking at nearly 938 million in 2023, underscores its commitment to innovation and market penetration. Meanwhile, Perrigo's steady rise to 1.27 billion suggests a focus on maintaining operational efficiency while expanding its product portfolio. These financial strategies highlight the diverse approaches companies take to thrive in the pharmaceutical industry, offering valuable insights for investors and stakeholders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025